Idian drugmaker Ranbaxy Pharmaceuticals has received approval from the U.S. FDA to manufacture and market doxycycline tablets at strengths of 50 mg, 75 mg and 100 mg in the U.S. market. The Ranbaxy formulation is bioequivalent to Adoxa, marketed by Bioglan Pharmaceutical.

Doxycycline is indicated for a variety of infections, including respiratory tract and urinary tract infections and skin infections, and as an adjuvant therapy for severe acne. Market sales for Adoxa were $57.2 million in 2005. The total doxycycline market achieved sales of $62.7 million, said Ranbaxy.